Interpace Biosciences, Inc. (IDXG) shareholders
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Ownership
Who owns Interpace Biosciences's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| AMP-18 Management Company Limited Partnership Joint filing with Ampersand 2018 Limited Partnership (76.00%), Amp-18 Mc LLC (76.00%) | 13,861,386 | 76.00% | 13D (active) amendment | Oct 11, 2024 |
| 1315 Capital II, L.P. Joint filing with 1315 Capital Management II, LLC (68.00%) | 9,405,940 | 68.00% | 13D (active) amendment | Oct 11, 2024 |
| Douglas M. Singer | 227,046 | 5.15% | 13G (passive) amendment | Dec 31, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas W. Burnell | CEO, President & Chairman, Director | 2,048,530 | 7.40% | Aug 20, 2026 |
| Christopher McCarthy | CFO & COO | 323,800 | 1.17% | Aug 20, 2026 |
| Stephen J. Sullivan | Director | 24,583 | 0.09% | Aug 20, 2026 |
| Vijay Aggarwal | Director | – | – | Aug 20, 2026 |
| Joseph D. Keegan | Director | 17,569 | 0.06% | Aug 20, 2026 |
| Fortunato R. Rocca | Director | – | – | Aug 20, 2026 |
| 1315 Capital II, L.P. | 10% owner | 9,405,941 | 33.96% | Feb 17, 2026 |
| 2018 Limited Partnership Ampersand | 10% owner | 13,861,386 | 50.04% | Feb 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christopher McCarthy CFO & COO | Aug 20, 2026 | Option exercise | +277,009 | – | – | 323,800 |
| Thomas W. Burnell CEO, President & Chairman, Director | Aug 20, 2026 | Option exercise | +1,966,763 | – | – | 2,037,645 |
| Thomas W. Burnell CEO, President & Chairman, Director | Aug 20, 2026 | Tax withholding | −581,718 | $1.61 | $936.57K | 1,455,927 |
| 1315 Capital II, L.P. 10% owner | Jan 20, 2026 | Conversion | +9,405,941 | $2.02 | $19.00M | 9,405,941 |
| 2018 Limited Partnership Ampersand 10% owner | Jan 20, 2026 | Conversion | +13,861,386 | $2.02 | $28.00M | 13,861,386 |
| Christopher McCarthy Chief Financial Officer | Dec 1, 2024 | Option exercise | +1,111 | – | – | 46,791 |
| Christopher McCarthy Chief Financial Officer | Jul 27, 2024 | Option exercise | +15,112 | – | – | 45,680 |
| Christopher McCarthy Chief Financial Officer | Feb 1, 2024 | Option exercise | +6,045 | – | – | 30,568 |
| Christopher McCarthy Chief Financial Officer | Feb 1, 2024 | Award | +10,000 | – | – | 45,644 |
| Christopher McCarthy Chief Financial Officer | Jan 31, 2024 | Option exercise | +7,556 | – | – | 24,523 |
| Christopher McCarthy Chief Financial Officer | Dec 1, 2023 | Option exercise | +1,095 | – | – | 16,967 |
| Christopher McCarthy Chief Financial Officer | Jul 31, 2023 | Option exercise | +7,556 | – | – | 15,872 |
| Christopher McCarthy Chief Financial Officer | Jul 31, 2023 | Award | +25,000 | – | – | 35,644 |
| Thomas W. Burnell President & CEO, Director | May 21, 2021 | Buy | +10,855 | $8.68 | $94.22K | 10,855 |
| Thomas John Freeburg Chief Financial Officer | Mar 10, 2021 | Award | +50,000 | – | – | 52,000 |
| Peter Kamin 10% owner | Mar 1, 2021 | Buy | +8,252 | $3.08 | $25.42K | 133,186 |
| Peter Kamin 10% owner | Mar 1, 2021 | Buy | +2,862 | $3.08 | $8.81K | 44,670 |
| Peter Kamin 10% owner | Mar 1, 2021 | Buy | +14,726 | $3.08 | $45.36K | 234,805 |
| Peter Kamin 10% owner | Mar 1, 2021 | Buy | +16,360 | $3.08 | $50.39K | 270,108 |
| Peter Kamin 10% owner | Feb 26, 2021 | Buy | +2,897 | $3.17 | $9.18K | 41,808 |
| Peter Kamin 10% owner | Feb 26, 2021 | Buy | +8,333 | $3.17 | $26.42K | 124,934 |
| Peter Kamin 10% owner | Feb 26, 2021 | Buy | +14,946 | $3.17 | $47.38K | 253,748 |
| Peter Kamin 10% owner | Feb 26, 2021 | Buy | +14,874 | $3.17 | $47.15K | 220,079 |
| Robert J. Gorman Director | Jan 29, 2021 | Award | +12,438 | $4.02 | $50.00K | 18,759 |
| Thomas W. Burnell President and CEO, Director | Dec 1, 2020 | Award | +125,000 | – | – | 225,000 |
| Thomas W. Burnell President and CEO, Director | Dec 1, 2020 | Award | +100,000 | – | – | 225,000 |
| James Early – | Jul 29, 2020 | Option exercise | +5,000 | – | – | 7,125 |
| Jack E. Stover President and CEO, Director | Mar 12, 2020 | Award | +7,188 | – | – | 30,271 |
| Robert J. Gorman Director | Jan 29, 2020 | Award | +6,321 | $7.91 | $50.00K | 6,321 |
| Gregory Richard Chief Commerical Officer | Mar 13, 2019 | Award | +39,528 | – | – | 84,169 |
| James Early Chief Financial Officer | Mar 13, 2019 | Award | +26,340 | – | – | 43,340 |
| Jack E. Stover President and CEO, Director | Mar 13, 2019 | Award | +86,922 | – | – | 427,300 |
| Thomas John Freeburg Chief Accounting Officer | Mar 13, 2019 | Award | +2,000 | – | – | 2,000 |
| Jack E. Stover President and CEO, Director | Dec 5, 2018 | Award | +87,000 | – | – | 340,378 |
| Gregory Richard Chief Commerical Officer | Dec 5, 2018 | Award | +13,400 | – | – | 44,641 |
| James Early Chief Financial Officer | Dec 5, 2018 | Award | +3,000 | – | – | 17,000 |
| Jack E. Stover President and CEO, Director | Dec 5, 2018 | Award | +60,000 | – | – | 313,378 |
| Joseph D. Keegan Director | Mar 7, 2018 | Award | +4,800 | – | – | 17,569 |
| Stephen J. Sullivan Director | Mar 7, 2018 | Award | +4,800 | – | – | 24,583 |
| Gregory Richard Chief Commerical Officer | Mar 7, 2018 | Award | +28,000 | – | – | 31,241 |
| James Early Chief Financial Officer | Mar 7, 2018 | Award | +14,000 | – | – | 14,000 |
| Jack E. Stover President and CEO, Director | Mar 7, 2018 | Award | +56,000 | – | – | 75,738 |
| Felice Schnoll-Sussman Director | Mar 7, 2018 | Award | +4,800 | – | – | 4,800 |
| Gregory Richard Chief Commerical Officer | Feb 26, 2018 | Option exercise | +2,000 | – | – | 3,241 |
| Harry Glorikian Director | Feb 3, 2016 | Award | +127,696 | $0.47 | $60.02K | 127,696 |
| Joseph D. Keegan Director | Feb 3, 2016 | Award | +127,696 | $0.47 | $60.02K | 127,696 |
| Stephen J. Sullivan Director | Feb 3, 2016 | Award | +100,000 | $0.47 | $47.00K | 197,828 |
| Jack E. Stover Interim President and CEO, Director | Feb 3, 2016 | Award | +100,000 | $0.53 | $53.00K | 197,378 |
| Graham G. Miao CFO | Dec 28, 2015 | Tax withholding | −69,020 | $0.53 | $36.58K | 142,852 |
| Gerald R. Melillo JR President, Sales Services | Dec 1, 2015 | Sale | −1,748 | $0.77 | $1.35K | 130,173 |
| Gerald R. Melillo JR President, Sales Services | Nov 30, 2015 | Sale | −765 | $0.80 | $612 | 131,921 |
| Gerald R. Melillo JR President, Sales Services | Nov 25, 2015 | Sale | −4,262 | $0.78 | $3.32K | 132,686 |
| Gerald P. Belle Director | Jun 3, 2015 | Award | +45,455 | $1.32 | $60.00K | 120,686 |
| John Federspiel Director | Jun 3, 2015 | Award | +34,091 | $1.32 | $45.00K | 100,378 |
| Heinrich Dreismann Director | Jun 3, 2015 | Award | +34,091 | $1.32 | $45.00K | 50,177 |
| Jack E. Stover Director | Jun 3, 2015 | Award | +34,091 | $1.32 | $45.00K | 97,378 |
| Stephen J. Sullivan Director | Jun 3, 2015 | Award | +34,091 | $1.32 | $45.00K | 97,828 |
| Gerald P. Belle Director | Jun 3, 2015 | Award | +45,455 | $1.32 | $60.00K | 143,086 |
| Nancy Lurker CEO, Director | Mar 5, 2015 | Award | +444,364 | $1.73 | $768.75K | 871,681 |
| Gerald R. Melillo JR President, Sales Services | Feb 24, 2015 | Award | +91,217 | $1.85 | $168.75K | 136,948 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Interpace Biosciences's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?